2018
DOI: 10.1093/jtm/tay110
|View full text |Cite
|
Sign up to set email alerts
|

Tafenoquine for travelers' malaria: evidence, rationale and recommendations

Abstract: BackgroundEndemic malaria occurring across much of the globe threatens millions of exposed travelers. While unknown numbers of them suffer acute attacks while traveling, each year thousands return from travel and become stricken in the weeks and months following exposure. This represents perhaps the most serious, prevalent and complex problem faced by providers of travel medicine services. Since before World War II, travel medicine practice has relied on synthetic suppressive blood schizontocidal drugs to prev… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
45
0
3

Year Published

2019
2019
2022
2022

Publication Types

Select...
4
2
1

Relationship

0
7

Authors

Journals

citations
Cited by 49 publications
(48 citation statements)
references
References 103 publications
0
45
0
3
Order By: Relevance
“…The second top-ranked drug is Tafenoquine which is an orally-active 8-aminoquinoline, a long-acting analog of primaquine, anti-malarial medicine developed by GlaxoSmithKline and 60 Degrees Pharmaceuticals [23,24]. The drug was FDA-approved for the radical cure of Plasmodium vivax (P. vivax) malaria and the prophylaxis of malaria in 2018.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…The second top-ranked drug is Tafenoquine which is an orally-active 8-aminoquinoline, a long-acting analog of primaquine, anti-malarial medicine developed by GlaxoSmithKline and 60 Degrees Pharmaceuticals [23,24]. The drug was FDA-approved for the radical cure of Plasmodium vivax (P. vivax) malaria and the prophylaxis of malaria in 2018.…”
Section: Resultsmentioning
confidence: 99%
“…The drug was FDA-approved for the radical cure of Plasmodium vivax (P. vivax) malaria and the prophylaxis of malaria in 2018. The drug is active against pre-erythrocytic, erythrocytic forms and the gametocytes of Plasmodium species that include P. falciparum and P. vivax [23,24]. Clinical trials for this drug may be also recommended.…”
Section: Resultsmentioning
confidence: 99%
“…During the last few years, exploration of N-heterocycles, particularly quinolone molecules, is a rapidly emerging area due to their wide applications [1,2] in pharmaceuticals, clinically used drugs and agrochemicals. [3][4][5][6][7] Quinoline based molecules like albaconazole has been used for its antibacterial and antifungal activity, [8][9][10] tafenoquin as an antimalarial drug, [11,12] afloqualone as an anticancer and muscle relaxant drug [13,14] and cliquinol for its antiprotozoal activity [15,16] (Figure 1).…”
Section: Introductionmentioning
confidence: 99%
“…However, in 2018, the Therapeutic Goods Administration in Australia and the Food and Drug Administration in the United States granted licences for tafenoquine for the radical cure of P. vivax malaria and for malaria chemoprophylaxis. Both primaquine and tafenoquine are 8‐aminoquinoline antimalarial drugs that can cause severe haemolysis in individuals with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency . Primaquine is rapidly metabolised and eliminated from the body, with a half‐life of 6 hours .…”
mentioning
confidence: 99%
“…Both primaquine and tafenoquine are 8‐aminoquinoline antimalarial drugs that can cause severe haemolysis in individuals with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency . Primaquine is rapidly metabolised and eliminated from the body, with a half‐life of 6 hours . Radical cure of latent infection is achieved with daily administration, the total dose spread over 14 days to improve tolerability.…”
mentioning
confidence: 99%